Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Could spirulina and seaweed lower your heart disease risk?

NCT ID NCT07173062

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study tests whether taking spirulina (a microalgae) or seaweed (Gelidium corneum) supplements for 20 weeks can improve markers of heart health and change gut bacteria in people at high risk for heart disease. The trial includes 150 adults aged 50 or older with conditions like diabetes, heart disease, or chronic kidney disease. Participants are randomly assigned to receive spirulina, seaweed, or a placebo, and researchers measure changes in blood chemicals and gut microbes.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Spirulina (microalgae) and Gelidium corneum (macroalgae/seaweed) dietary supplements
What this could lead to
If it works, this could point toward a simple, natural way to improve heart health and gut bacteria in people with conditions like diabetes or heart disease.
What could go wrong
This is an early-stage trial with only 150 participants, so results may not apply to everyone. Supplements can have mild side effects, and the benefits may be small or not last long.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 150 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2025

Expected to finish

Aug 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

50 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * ≥50 years * BMI ≥20 kg/m2 * History of stroke, coronary artery disease, myocardial infarction, peripheral artery disease, chronic kidney disease (eGFR \<75 ml/min at least for 3 months), albuminuria \>300 mg/g, or diabetes mellitus * No antibiotics in the previous 30 days * If a woman, she must be a woman of non-childbearing potential. That is, she must be: * Surgically sterilized (e.g. underwent hysterectomy, bilateral salpingectomy or bilateral oophorectomy); * Clinically diagnosed infertile; * In a post-menopausal state, defined as no menses for 12 months without an alternative medical cause. * A woman patient of childbearing potential must have a negative serum pregnancy test at Visit 0 (Day 0) and must agree to use consistently and correctly (from 28 days prior to first study treatment administration until at least 7 days after last study treatment administration) one of the following highly effective methods of contraception: * Abstinence of heterosexual intercourse (when this is in line with preferred and usual lifestyle of the subject); * Progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable, implantable); * Combined (oestrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal, transdermal); * Intrauterine device; * Intrauterine hormone-releasing system; * Bilateral tubal occlusion; * Vasectomized partner, who has received medical assessment of the surgical success, or clinically diagnosed infertile partner. Exclusion Criteria: * Unwilling to sign the informed consent form (if the patient wants to participate but cannot sign for any reason, then a third-person testimony may sign/complete the informed consent form on the patient's behalf). * Involvement in the planning and/or conduct of the study (applies to both Investigator staff and/or staff at the study site). * Participation in another clinical study with an investigational product during the last month. * In participants recruited at Unidade Local de Saúde de São João, the exclusion criteria applied is estimated Glomerular Filtration Rate (eGFR) \<30 ml/min/1.73m2 estimated with the CKD-EPI (2021) formula or dialysis. For participants recruited at community, this exclusion criteria is adapted for diagnosis of end-stage renal disease or dialysis (no need to quantify the eGFR).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Albuminuria are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    1 site. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Unidade Local de Saúde de São João

    RECRUITING

    Porto, 4200-319, Portugal

More trials for these conditions

Other studies related to the condition(s) this trial covers.